Aspirin and myocardial infarction

1987 ◽  
Vol 25 (5) ◽  
pp. 17-19
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Coronary Thrombosis ◽  
Food And Drug Administration ◽  
Preventive Effect ◽  
Vascular Disorders ◽  
Heart Attacks ◽  
The Us

When we last reviewed the use of aspirin in vascular disorders we concluded that a preventive effect in coronary thrombosis was uncertain.1 In 1985 the US Food and Drug Administration accepted, after reviewing the evidence, that aspirin can reduce the likelihood of heart attacks for some patients.2 How strong is this evidence?

Peritrate is no longer claimed to aid survival

1966 ◽  
Vol 4 (12) ◽  
pp. 47-48
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Pentaerythritol Tetranitrate ◽  
Sustained Action ◽  
The Us ◽  
Action Preparation

On February 28 the US Food and Drug Administration took the unprecedented step of seizing stocks of Peritrate SA (Warner-Chileott Labs), a sustained-action preparation of pentaerythritol tetranitrate. This was done because the FDA judged advertisements for the drug to be ‘false and misleading’. They implied that the drug increased survival after myocardial infarction by asking ‘Is Peritrate life - sustaining?’, clearly inviting the answer ‘yes’.

scholarly journals Impact of the US Food and Drug Administration–Approved Sex-Specific Cutoff Values for High-Sensitivity Cardiac Troponin T to Diagnose Myocardial Infarction

Circulation ◽  
2018 ◽  
Vol 137 (17) ◽  
pp. 1867-1869 ◽  
Author(s):  
Maria Rubini Gimenez ◽  
Patrick Badertscher ◽  
Raphael Twerenbold ◽  
Jasper Boeddinghaus ◽  
Thomas Nestelberger ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Drug Administration ◽  
Cardiac Troponin ◽  
Troponin T ◽  
Food And Drug Administration ◽  
High Sensitivity ◽  
Cardiac Troponin T ◽  
Cutoff Values ◽  
The Us

scholarly journals 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

2021 ◽  
Vol 14 (2) ◽  
pp. 145
Author(s):  
Othman Al Musaimi ◽  
Danah Al Shaer ◽  
Fernando Albericio ◽  
Beatriz de la Torre
Keyword(s):  
Adverse Effects ◽  
Global Health ◽  
Drug Administration ◽  
Mode Of Action ◽  
Chemical Structure ◽  
Food And Drug Administration ◽  
Health Crisis ◽  
New Drug ◽  
Target Mode ◽  
The Us

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

Sign in / Sign up

Export Citation Format

Share Document